Hye Seong

Dr. Hye Seong

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JYJin Gu Yoon
Jin Gu Yoon
JYJung Yoon
Jung Yoon
JSJoon Young Song
Joon Young Song
SYSoo-Young Yoon
Soo-Young Yoon
Chae Seung LimChae Seung Lim
Chae Seung Lim
WKWoo Joo Kim
Woo Joo Kim
Yoon JG, et al. J Korean Med Sci. 2020 Mar;35(20):e195. https://doi.org/10.3346/jkms.2020.35.e195

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JNJi Yun Noh
Ji Yun Noh
HSHye Seong
Hye Seong
JYJin Gu Yoon
Jin Gu Yoon
JSJoon Young Song
Joon Young Song
HCHee Jin Cheong
Hee Jin Cheong
WKWoo Joo Kim
Woo Joo Kim
Noh JY, et al. J Korean Med Sci. 2020 Mar;35(19):e182. https://doi.org/10.3346/jkms.2020.35.e182

Verified
Journal Article
Open access
PDF file
HSHye Seong
Hye Seong
JKJung Ho Kim
Jung Ho Kim
JKjun hyoung kim
jun hyoung kim
WLWoon Ji Lee
Woon Ji Lee
JAJin Young Ahn
Jin Young Ahn
SJSu Jin Jeong
Su Jin Jeong
Elizabethkingia species (spp.), which can colonize hospital environments, are emerging nosocomial pathogens presenting high mortality. Due to their intrinsic resistance to a broad range of antibiotics, optimal antibiotic dosage has yet to be determined against infections caused by Elizabethkingia spp. This study aimed to investigate the risk factors for the mortality of infections caused by Elizabethkingia spp. and assess the clinical implications of their antimicrobial susceptibility patterns. Data from 210 patients affected by Elizabethkingia-induced pneumonia and bacteremia between 1 November 2005 and 31 May 2016, were analyzed. Further antimicrobial susceptibility tests for moxifloxacin, rifampin, and vancomycin using Elizabethkingia isolates were performed to compensate for the Elizabethkingia spp. susceptibility panel in patients affected after 2013. The mean age of the patients was 66.5 ± 18 years and the 28-day mortality rate was 25.2% (53/210). In the univariate analysis, history of prior stay in an intensive care unit, central venous catheter use, presented thrombocytopenia, immunocompetent status, a high simplified acute physiology score II (SAPS II score), a high C-reactive protein (CRP)/albumin ratio on the day of isolation and seven days later, and a high minimum inhibitory concentration (MIC) value of rifampin were significantly associated with a higher mortality rate. In the multivariate logistic regression analysis, the MIC values of rifampin (odds ratio (OR): 1.045; 95% confidence interval (CI): 1.006–1.085; p = 0.023), SAPS II score (OR: 1.053; 95% CI: 1.022–1.084; p = 0.001), and initial CRP/albumin ratio (OR: 1.030; 95% CI: 1.009–1.051; p = 0.004) were significantly associated with 28-day mortality. To reduce the mortality associated with Elizabethkingia infections, prediction of the clinical course using initial CRP/albumin ratio and SAPS II and early intervention are essential. Rifampin is a promising candidate as the drug of choice in treating Elizabethkingia infections.

1 January 2024 in Infection & Chemotherapy
Verified
Journal Article
Open access
SPSe Yoon Park
Se Yoon Park
YBYae Jee Baek
Yae Jee Baek
JKJung Ho Kim
Jung Ho Kim
HSHye Seong
Hye Seong
BKBongyoung Kim
Bongyoung Kim
KTKorean Society For Antimicrobial Therapy
Korean Society For Antimicrobial Therapy
Park SY, et al. Infect Chemother. 2024 Aug;56:e35. https://doi.org/10.3947/ic.2024.0038

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JNJi Yun Noh
Ji Yun Noh
YSYu Bin Seo
Yu Bin Seo
JYJin Gu Yoon
Jin Gu Yoon
HSHye Seong
Hye Seong
HHHakjun Hyun
Hakjun Hyun
JSJoon Young Song
Joon Young Song
Noh JY, et al. J Korean Med Sci. 2020 Jul;35(33):e311. https://doi.org/10.3346/jkms.2020.35.e311

9 August 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
YJYong Duk Jeon
Yong Duk Jeon
HSHye Seong
Hye Seong
DKDokyun Kim
Dokyun Kim
MAMi Young Ahn
Mi Young Ahn
IJIn Young Jung
In Young Jung
NKNam Su Ku
Nam Su Ku
Several studies have evaluated the impact of matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) combined with antimicrobial stewardship in patients with positive blood cultures; clinical outcomes improved. However, in many hospitals, antimicrobial stewardship is not available because of restricted medical resources. Thus, we investigated the impact of evaluation by MALDI-TOF MS on the clinical outcomes of patients with bacteremia and fungemia treated in a clinical setting lacking an antimicrobial stewardship program (ASP). We designed a pre–post quasi experimental study and retrospectively reviewed the medical records of patients aged > 18 years old with bacteremia and fungemia during two periods: October–December 2012 and October–December 2013. Conventional methods were used to detect microbial pathogens in 2012, and MALDI-TOF MS was employed in 2013. Clinical outcomes compared between periods were the time to pathogen identification, time to effective therapy, 30-day all-cause mortality, time to microbiological clearance, length of ICU stay, and rate of recurrence of the same bloodstream infection (BSI). A total of 556 patients were enrolled; 302 patients in 2012, and 254 in 2013. The use of MALDI-TOF MS without an ASP reduced the time to pathogen identification (86.4 vs. 63.5 h, P < 0.001) but did not significantly reduce the time to effective therapy (27.4 vs. 23.2 h, P = 0.187). Also, none of the following differed significantly between the two periods: mortality (17.5 vs. 15.7%, P = 0.571), the time to microbiological clearance (3.6 vs. 3.7 days, P = 0.675), the length of ICU stay (16.8 vs. 14.7 days, P = 0.706), and the recurrence rate of the same BSI (5.0 vs. 2.8%, P = 0.183). The use of MALDI-TOF MS alone in a setting lacking an ASP did not afford clinical benefits. An ASP combined with MALDI-TOF MS is necessary to improve clinical outcomes.